Fractyl Health (NASDAQ:GUTS) Reaches New 12-Month Low – Time to Sell?

Fractyl Health, Inc. (NASDAQ:GUTS) hit a new 52-week low on Monday. The company traded as low as $4.33 and last traded at $4.4630, with a volume of 18808 shares trading hands. The stock had previously closed at $4.8792.

Key Headlines Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Neutral Sentiment: Trading in GUTS was temporarily halted under a “news pending” designation on October 5. The notice did not provide details about the pending news or indicate how long the halt would last.
• Neutral Sentiment: A comparison article reviewed Fractyl Health alongside Viridian Therapeutics, but the available report details do not identify a specific new development likely to materially affect GUTS. Fractyl Health and Viridian Therapeutics comparison
• Negative Sentiment: Pomerantz LLP announced a federal securities class action against Fractyl Health and certain officers. The complaint alleges violations of federal securities laws and seeks damages for investors during the specified class period. Pomerantz Fractyl class action announcement
• Negative Sentiment: Multiple law firms—including Faruqi & Faruqi, Bragar Eagel & Squire, Howard G. Smith, Bernstein Liebhard, Glancy Prongay Wolke & Rotter, Levi & Korsinsky, Bronstein Gewirtz & Grossman, and Robbins—are soliciting affected shareholders or reminding them about the October 20 lead-plaintiff deadline. The unusually high volume of notices may reinforce concerns about litigation exposure and investor losses. Faruqi Fractyl deadline alert
• Negative Sentiment: The central allegations involve Fractyl’s disclosures about operational problems and an “outlier” site in its REMAIN-1 clinical study. Plaintiffs claim the company promoted Revita DMR weight-maintenance data before disclosing that the site skewed results; one notice states that shares subsequently fell 74.86%. These are allegations, not established findings, but they could increase legal costs, uncertainty, and reputational risk. Fractyl shareholder alert

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on GUTS shares. Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Craig Hallum began coverage on shares of Fractyl Health in a research note on Wednesday, July 1st. They set a “buy” rating and a $48.00 price target for the company. Finally, Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Fractyl Health has an average rating of “Hold” and a consensus target price of $66.00.

Fractyl Health Stock Up 0.2%

The business has a 50-day simple moving average of $7.58 and a two-hundred day simple moving average of $8.14. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The company has a market capitalization of $60.60 million, a price-to-earnings ratio of -0.43 and a beta of 2.42.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Monday, August 10th. The company reported ($1.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.18. As a group, equities analysts predict that Fractyl Health, Inc. will post -6.3 EPS for the current year.

Hedge Funds Weigh In On Fractyl Health

A number of large investors have recently bought and sold shares of GUTS. 683 Capital Management LLC boosted its holdings in shares of Fractyl Health by 30.1% in the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after acquiring an additional 1,397,620 shares in the last quarter. Catalio Capital Management LP raised its holdings in Fractyl Health by 5.3% during the fourth quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company’s stock worth $12,082,000 after purchasing an additional 277,630 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in Fractyl Health in the second quarter valued at about $8,968,058. Bank of America Corp DE acquired a new stake in Fractyl Health in the second quarter valued at about $4,791,000. Finally, Atom Investors LP purchased a new stake in Fractyl Health in the 4th quarter valued at approximately $4,143,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.